AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients taking more than 5 medications
Number of subjects: 14511
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug events (ADE) detected during the ED visit
Number of subjects: 14511
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalised patients with bleeding as an ADE symptom
Number of subjects: 14511
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalised patients with metabolic disorders as an ADE symptom
Number of subjects: 14511
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables associated with increased hospital admission
Number of subjects: 14511
Study 33866662 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-related variables associated with increased hospital admission
Number of subjects: 14511
Study 33866681 — intervention group
Group type: EXPERIMENTAL
Intervention: JGG endoscope
Number of subjects: 21
Study 33866818 — intervention group
Group type: EXPERIMENTAL
Intervention: 6- to 8-week magnetic resonance imaging (MRI)
Number of subjects: 89
Study 33866818 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 89
Study 33866818 — intervention group
Group type: EXPERIMENTAL
Intervention: Index multi-infarct pattern
Number of subjects: 89
Study 33866829 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System via thoracotomy approach
Number of subjects: 144
Study 33866938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 33866938 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (single-agent paclitaxel or doxorubicin)
Number of subjects: 0
Study 33866936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 2-3
Number of subjects: 1189
Study 33866936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 4-5
Number of subjects: 1189
Study 33866936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization for Rutherford 6
Number of subjects: 1189
Study 33867192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (18 mg) plus everolimus (5 mg) orally once daily
Number of subjects: 31
Study 33867478 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and bevacizumab
Number of subjects: 0
Study 33867478 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 33867478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab and bevacizumab biosimilar
Number of subjects: 0
Study 33867478 — intervention group
Group type: EXPERIMENTAL
Intervention: Donafenib
Number of subjects: 0
Study 33867478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 0
Study 33867478 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 0
Study 33867478 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 33867481 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscadine grape extract (MGE) capsules by mouth twice daily, 320 to 1600 mg total phenolics/d for 4 weeks
Number of subjects: 23
Study 33868016 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 323
Study 33868016 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy obese patients
Number of subjects: 323
Study 33868016 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy obese patients
Number of subjects: 323
Study 33868050 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting Only
Number of subjects: 0
Study 33868050 — intervention group
Group type: COMPARATOR
Intervention: Imagery Rescripting and Schema Therapy
Number of subjects: 0
Study 33868061 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-derived communication training for caregivers; 4 sessions of 60 minutes each
Number of subjects: 31
Study 33868150 — intervention group
Group type: EXPERIMENTAL
Intervention: Early anticoagulation with Edoxaban
Number of subjects: 0
Study 33868150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10 expression during active TB
Number of subjects: 132
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-3 expression
Number of subjects: 132
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 expression
Number of subjects: 132
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1RA expression
Number of subjects: 132
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10 expression
Number of subjects: 132
Study 33868272 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1α expression
Number of subjects: 132
Study 33868439 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE)
Number of subjects: 63
Study 33868439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 33868707 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendinopathy (AT) patients
Number of subjects: 80
Study 33869653 — intervention group
Group type: EXPERIMENTAL
Intervention: MND promoter-driven CAR-T cells
Number of subjects: 14
Study 33869653 — intervention group
Group type: COMPARATOR
Intervention: EF1α promoter-driven CAR-T cells
Number of subjects: 14
Study 33869765 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office tympanostomy tube placement using a single-pass device
Number of subjects: 229
Study 33870087 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme for deconditioned cancer survivors
Number of subjects: 0
Study 33870149 — intervention group
Group type: EXPERIMENTAL
Intervention: EpAbs (INM005)
Number of subjects: 245
Study 33870149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 33870151 — intervention group
Group type: EXPERIMENTAL
Intervention: TVB-2640 (60 mg/m) as monotherapy
Number of subjects: 136
Study 33870151 — intervention group
Group type: EXPERIMENTAL
Intervention: TVB-2640 with a taxane
Number of subjects: 136
Study 33870150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified approach to care (intervention)
Number of subjects: 2300
Study 33870150 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2300
Study 33870413 — intervention group
Group type: EXPERIMENTAL
Intervention: Karius microbial cell-free DNA sequencing test (KT)
Number of subjects: 55
Study 33870413 — intervention group
Group type: COMPARATOR
Intervention: Blood culture (BC) and standard microbiological testing (SMT)
Number of subjects: 55
Study 33870484 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1647
Study 33870705 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (LAAO)
Number of subjects: 50
Study 33870705 — intervention group
Group type: COMPARATOR
Intervention: Oral Anticoagulation (OAC)
Number of subjects: 50
Study 33871063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 587
Study 33871377 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mental health program (Happify for Teens) for 8 weeks
Number of subjects: 800
Study 33871377 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 800
Study 33871700 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating TNFrII levels in male patients with type 2 diabetes
Number of subjects: 761
Study 33871700 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating TNFrII levels in female patients with type 2 diabetes
Number of subjects: 761
Study 33871709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT scan
Number of subjects: 487
Study 33871709 — intervention group
Group type: COMPARATOR
Intervention: Negative chest CT findings
Number of subjects: 487
Study 33871807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mongersen 160 mg/day for 12 weeks
Number of subjects: 18
Study 33871807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mongersen (specific batch)
Number of subjects: 18
Study 33871830 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0
Study 33871888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies to LG3 (LG3-A)
Number of subjects: 93
Study 33871888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies to AT1R-AA
Number of subjects: 93
Study 33871888 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-positive for LG3-A and donor-specific antibody (DSA)
Number of subjects: 93
Study 33871888 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-positive for LG3-A and AT1R-AA
Number of subjects: 93
Study 33872131 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nanoparticles (exact dosage and duration not specified)
Number of subjects: 0
Study 33872184 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based onboarding procedures with human support for mHealth intervention
Number of subjects: 43
Study 33872334 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving Babies Lives (SBL) Care Bundle implementation
Number of subjects: 463630
Study 33873093 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel recombinant five-antigen Staphylococcus aureus vaccine
Number of subjects: 0
Study 33873199 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit COVID-19 vaccine
Number of subjects: 0
Study 33874911 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep disturbance
Number of subjects: 242
Study 33874975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ty21a immunization
Number of subjects: 0
Study 33874987 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 1346
Study 33874987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable patients
Number of subjects: 1346
Study 33874987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit patients
Number of subjects: 1346
Study 33874987 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients
Number of subjects: 1346
Study 33874987 — intervention group
Group type: COMPARATOR
Intervention: Frail patients across different age categories
Number of subjects: 1346
Study 33874987 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 1346
Study 33875560 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct endovascular thrombectomy (dEVT)
Number of subjects: 226
Study 33875560 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (BT; IV tissue plasminogen activator + EVT)
Number of subjects: 226
Study 33875611 — intervention group
Group type: EXPERIMENTAL
Intervention: PVSRIPO monotherapy (1, 2, or 3 injections with 21 days between injections)
Number of subjects: 12
Study 33875845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous olipudase alfa administered every 2 weeks with intrapatient dose escalation to 3 mg/kg
Number of subjects: 20
Study 33876222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous iron tracers administered before treatment and after intensive phase (8/12 weeks) and complete treatment (24 weeks)
Number of subjects: 18
Study 33876229 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antimicrobial treatment ≥1 day before delivery
Number of subjects: 189
Study 33876229 — intervention group
Group type: COMPARATOR
Intervention: No maternal antimicrobial treatment
Number of subjects: 189
Study 33876229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neonatal outcomes
Number of subjects: 189
Study 33876229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age <34 weeks
Number of subjects: 189
Study 33876337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative monitoring of renal region tissue oxygenation (SrtO2)
Number of subjects: 0
Study 33876337 — intervention group
Group type: COMPARATOR
Intervention: Cerebral and peripheral oxygenation monitoring
Number of subjects: 0
Study 33876469 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving pharmacogenomic results by mail
Number of subjects: 49
Study 33876576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily
Number of subjects: 0
Study 33877483 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical leaflet calcification (AC)
Number of subjects: 567
Study 33877483 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical leaflet calcification (SC)
Number of subjects: 567
Study 33877483 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for SC
Number of subjects: 567
Study 33877496 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training (twice weekly for six months)
Number of subjects: 41
Study 33877496 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 33877661 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D high-resolution anorectal manometry (3DHRAM)
Number of subjects: 43
Study 33877856 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg once daily
Number of subjects: 54
Study 33877856 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg twice daily
Number of subjects: 54
Study 33877856 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 400 mg once daily
Number of subjects: 54
Study 33877856 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS) treatment
Number of subjects: 54
Study 33878018 — intervention group
Group type: EXPERIMENTAL
Intervention: Before the second partial lockdown
Number of subjects: 2218
Study 33878018 — intervention group
Group type: COMPARATOR
Intervention: After the second partial lockdown
Number of subjects: 2218
Study 33878020 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote clinic visits during the COVID-19 pandemic
Number of subjects: 23
Study 33878020 — intervention group
Group type: COMPARATOR
Intervention: In-person clinic visits (pre-COVID-19 cohort)
Number of subjects: 23
Study 33878074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive SCAD patients
Number of subjects: 318
Study 33878074 — intervention group
Group type: COMPARATOR
Intervention: Normotensive SCAD patients
Number of subjects: 318
Study 33878339 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 506
Study 33878339 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD control subjects
Number of subjects: 506
Study 33878339 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with COPD
Number of subjects: 506
Study 33878776 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation with immunosuppressive therapy
Number of subjects: 12
Study 33878888 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for atrial fibrillation using a mobile, single-lead ECG device.
Number of subjects: 1019
Study 33878888 — intervention group
Group type: COMPARATOR
Intervention: Not undergoing screening (control group).
Number of subjects: 1019
Study 33879078 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 as the principal cause of death
Number of subjects: 155
Study 33879078 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 as a contributing cause of death
Number of subjects: 155
Study 33879078 — intervention group
Group type: EXPERIMENTAL
Intervention: Other comorbidities as the cause of death
Number of subjects: 155
Study 33879084 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for liver fat content
Number of subjects: 400
Study 33879084 — intervention group
Group type: EXPERIMENTAL
Intervention: MR elastography and vibration-controlled transient elastography for hepatic fibrosis
Number of subjects: 400
Study 33879084 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-fat separated whole body MRI for muscle composition and body fat distribution
Number of subjects: 400
Study 33879084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI for cardiac function, structure, and tissue characteristics
Number of subjects: 400
Study 33879090 — intervention group
Group type: EXPERIMENTAL
Intervention: Generative adversarial imputation nets (GAIN)
Number of subjects: 60000
Study 33879090 — intervention group
Group type: COMPARATOR
Intervention: missForest
Number of subjects: 60000
Study 33879090 — intervention group
Group type: COMPARATOR
Intervention: MICE
Number of subjects: 60000
Study 33879090 — intervention group
Group type: EXPERIMENTAL
Intervention: Computation speed of GAIN
Number of subjects: 60000
Study 33879094 — intervention group
Group type: COMPARATOR
Intervention: Swedish/COMPERA risk stratification method
Number of subjects: 432
Study 33879094 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk stratification strategy
Number of subjects: 432
Study 33879123 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 65
Study 33879180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 142
Study 33879180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 142
Study 33879180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 142
Study 33879180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal radiotherapy
Number of subjects: 142
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP)
Number of subjects: 243
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 243
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 243
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for PSP
Number of subjects: 243
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for CRP
Number of subjects: 243
Study 33879189 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) analysis for PCT
Number of subjects: 243
Study 33879206 — intervention group
Group type: EXPERIMENTAL
Intervention: PARACHUTE device implantation
Number of subjects: 6
Study 33879253 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 40
Study 33879253 — intervention group
Group type: COMPARATOR
Intervention: Education/support control condition
Number of subjects: 40
Study 33879253 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT intervention
Number of subjects: 40
Study 33879259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based self-sampled HPV testing
Number of subjects: 0
Study 33879259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based and community-based self-sampled HPV testing
Number of subjects: 0
Study 33879263 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single directly observed dose)
Number of subjects: 300
Study 33879263 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (7-day course)
Number of subjects: 300
Study 33879458 — intervention group
Group type: EXPERIMENTAL
Intervention: IMU-131 (B-cell epitope vaccine)
Number of subjects: 14
Study 33879458 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 cohort (50 μg dose)
Number of subjects: 14
Study 33879458 — intervention group
Group type: COMPARATOR
Intervention: C1 and C2 cohorts (10 and 30 μg doses)
Number of subjects: 14
Study 33879481 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I - Observational study on the prevalence of urinary incontinence and its associated factors; prevalence ratio used as an association measure.
Number of subjects: 0
Study 33879481 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II - Longitudinal study over 2 years; evaluates functional and continence decline, falls, hospitalisations, mortality, and impact of COVID-19.
Number of subjects: 0
Study 33879499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic OME patients
Number of subjects: 123
Study 33879499 — intervention group
Group type: COMPARATOR
Intervention: Controls (healthy subjects)
Number of subjects: 123
Study 33879515 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced blood glucose normalization (from 7.6±0.4 mmol/L to 4.5±0.07 mmol/L for 1 hour)
Number of subjects: 23
Study 33879515 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced blood glucose normalization
Number of subjects: 23
Study 33879515 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained at 4.9±0.1 mmol/L
Number of subjects: 23
Study 33879601 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg every 3 weeks for ≤2 years
Number of subjects: 50
Study 33879601 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage therapies including chemotherapies and immunotherapies
Number of subjects: 50
Study 33879722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration with Lactated Ringer Solution
Number of subjects: 2200
Study 33879819 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased coupling between right temporoparietal and anterior cingulate cortex for repeated objects
Number of subjects: 0
Study 33879819 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition suppression
Number of subjects: 0
Study 33879819 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial support for predictions of the Facilitation and Sharpening models in the left fusiform gyrus and left frontal cortex
Number of subjects: 0
Study 33880400 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopy
Number of subjects: 0
Study 33870087 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 0
Study 33880438 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity
Number of subjects: 1364
Study 33880438 — intervention group
Group type: COMPARATOR
Intervention: Intensive Therapy Unit (ITU) workers
Number of subjects: 1364
Study 33880438 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 1364
Study 33880438 — intervention group
Group type: COMPARATOR
Intervention: White HCWs
Number of subjects: 1364
Study 33880504 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated carbohydrate density
Number of subjects: 81954
Study 33880504 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated protein density
Number of subjects: 81954